In this phase @ trial we evaluated the efficacy and safety of the interferon-free combination of ABT-@ with ritonavir ( ABT-@ / r ) , ombitasvir ( also known as ABT-@ ) , dasabuvir ( also known as ABT-@ ) , and ribavirin for the retreatment of HCV in patients who were previously treated with peginterferon-ribavirin .